Yunong Gao

2.8k total citations · 1 hit paper
55 papers, 1.4k citations indexed

About

Yunong Gao is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, Yunong Gao has authored 55 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Reproductive Medicine, 22 papers in Oncology and 17 papers in Surgery. Recurrent topics in Yunong Gao's work include Ovarian cancer diagnosis and treatment (24 papers), PARP inhibition in cancer therapy (12 papers) and Endometrial and Cervical Cancer Treatments (12 papers). Yunong Gao is often cited by papers focused on Ovarian cancer diagnosis and treatment (24 papers), PARP inhibition in cancer therapy (12 papers) and Endometrial and Cervical Cancer Treatments (12 papers). Yunong Gao collaborates with scholars based in China, Ethiopia and United Kingdom. Yunong Gao's co-authors include Weijiao Gao, Yu Yang, Sijin Cheng, Jiafu Ji, Liang Jiang, Ranran Gao, Xiliang Wang, Zemin Zhang, Xueda Hu and Bin Zhang and has published in prestigious journals such as Cell, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Yunong Gao

54 papers receiving 1.4k citations

Hit Papers

A pan-cancer single-cell transcriptional atlas of tumor i... 2021 2026 2022 2024 2021 250 500 750

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yunong Gao China 15 555 552 510 235 210 55 1.4k
Takashi Miyatake Japan 19 306 0.6× 179 0.3× 213 0.4× 281 1.2× 188 0.9× 47 1.0k
Amal Kanbour‐Shakir United States 21 224 0.4× 156 0.3× 189 0.4× 214 0.9× 288 1.4× 55 1.2k
Mehran Ghaderi Sweden 23 319 0.6× 471 0.9× 219 0.4× 179 0.8× 159 0.8× 57 1.4k
Katsumi Tsukazaki Japan 18 452 0.8× 174 0.3× 245 0.5× 326 1.4× 161 0.8× 65 1.1k
Nader Husseinzadeh United States 18 270 0.5× 278 0.5× 296 0.6× 292 1.2× 256 1.2× 48 1.2k
Miriam Mints Sweden 18 285 0.5× 121 0.2× 124 0.2× 324 1.4× 193 0.9× 52 967
Mu‐Hsien Yu Taiwan 21 813 1.5× 85 0.2× 236 0.5× 298 1.3× 186 0.9× 43 1.4k
Ting-Chang Chang Taiwan 19 405 0.7× 91 0.2× 316 0.6× 478 2.0× 406 1.9× 30 1.4k
Rhona J. McVey United Kingdom 19 350 0.6× 144 0.3× 220 0.4× 198 0.8× 135 0.6× 32 991
Mark Messing United States 13 261 0.5× 87 0.2× 420 0.8× 121 0.5× 225 1.1× 31 1.1k

Countries citing papers authored by Yunong Gao

Since Specialization
Citations

This map shows the geographic impact of Yunong Gao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yunong Gao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yunong Gao more than expected).

Fields of papers citing papers by Yunong Gao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yunong Gao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yunong Gao. The network helps show where Yunong Gao may publish in the future.

Co-authorship network of co-authors of Yunong Gao

This figure shows the co-authorship network connecting the top 25 collaborators of Yunong Gao. A scholar is included among the top collaborators of Yunong Gao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yunong Gao. Yunong Gao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Wang, Wei, Xiao-Ting Li, Yunong Gao, Hong Zheng, & Min Gao. (2023). A nomogram prediction model for the TP53mut subtype in endometrial cancer based on preoperative noninvasive parameters. BMC Cancer. 23(1). 720–720. 2 indexed citations
3.
Xia, Lingfang, Qi Zhou, Yunong Gao, et al.. (2022). A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma. Nature Communications. 13(1). 7581–7581. 17 indexed citations
4.
Shu, Tong, Zhipeng Zhou, Jing Bai, et al.. (2022). Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer. Gynecologic Oncology. 168. 135–143. 1 indexed citations
5.
Cheng, Sijin, Ziyi Li, Ranran Gao, et al.. (2021). A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 184(3). 792–809.e23. 820 indexed citations breakdown →
6.
Wu, Xiaotong, Lingying Wu, Yumei Wu, et al.. (2021). Evaluation of the sexual quality of life and sexual function of cervical cancer survivors after cancer treatment: a retrospective trial. Archives of Gynecology and Obstetrics. 304(4). 999–1006. 25 indexed citations
7.
Zheng, Hong, Tong Shu, Shan Zhu, et al.. (2021). Construction and Validation of a Platinum Sensitivity Predictive Model With Multiple Genomic Variations for Epithelial Ovarian Cancer. Frontiers in Oncology. 11. 725264–725264. 9 indexed citations
8.
Wang, Sha, Hongwu Wen, Yunong Gao, et al.. (2021). Assessment of Pelvic Floor Function and Quality of Life in Patients Treated for Cervical Cancer: A Multicenter Retrospective Study. Gynecologic and Obstetric Investigation. 86(4). 353–360. 11 indexed citations
9.
Wang, Jing, Xiaohua Wu, Jianqing Zhu, et al.. (2021). Safety assessment of niraparib individualized starting dose in patients with platinum-sensitive recurrent ovarian cancer: A randomized, double-blind, placebo-controlled, phase III NORA trial.. Journal of Clinical Oncology. 39(15_suppl). 5535–5535. 1 indexed citations
12.
Gao, Min, et al.. (2020). Choice for prophylactic antibiotics: Cefazolin plus metronidazole or cefoxitin alone for endometrial cancer surgical staging. Journal of obstetrics and gynaecology research. 46(9). 1864–1870. 3 indexed citations
13.
Gao, Yunong, et al.. (2019). Therapeutic value of selective lymphadenectomy in interval debulking surgery for stage IIIc and IV epithelial ovarian cancer. International Journal of Gynecological Cancer. 29(4). 761–767. 13 indexed citations
14.
Wu, Lingying, Jianqing Zhu, Rutie Yin, et al.. (2019). Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Annals of Oncology. 30. ix79–ix79. 4 indexed citations
15.
Owen, Sioned, Fiona Ruge, Yunong Gao, et al.. (2017). ShenLingLan Influences the Attachment and Migration of Ovarian Cancer Cells Potentially through the GSK3 Pathway. SHILAP Revista de lepidopterología. 4(1). 10–10. 4 indexed citations
16.
Kim, Hoon-Kyo, Ruey-Kuen Hsieh, Alexandre Chan, et al.. (2014). Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice. Supportive Care in Cancer. 23(1). 293–300. 16 indexed citations
17.
Zheng, Hong, et al.. (2013). [Expression of serum human epididymis protein 4 in epithelial ovarian cancer and its correlation with prognosis].. PubMed. 35(6). 445–9. 4 indexed citations
18.
Cao, Kun, Min Gao, Ying‐Shi Sun, et al.. (2011). Apparent diffusion coefficient of diffusion weighted MRI in endometrial carcinoma—Relationship with local invasiveness. European Journal of Radiology. 81(8). 1926–1930. 37 indexed citations
19.
Jiang, Guo‐Qing, Yunong Gao, Min Gao, et al.. (2011). Clinicopathological features and treatment of extremity bone metastasis in patients with endometrial carcinoma: a case report and review.. PubMed. 124(4). 622–6. 11 indexed citations
20.
Yan, Xin, et al.. (2008). [Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].. PubMed. 30(4). 298–301. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026